NEW YORK (GenomeWeb News) – Activiomics announced recently a research deal with Kyowa Hakko Kirin for use of Activiomics' mass spectrometry-based technology to "elucidate signaling mechanism of lead compounds in relevant cell-based systems."

Under the deal, the Japanese pharmaceutical firm will use Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology to identify important biomarkers that can be used in the drug-discovery process.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.